The US FDA recently approved mavacamten, a first-in-class myosin modulator, for obstructive hypertrophic cardiomyopathy. By targeting actin mechanobiology, myosin modulators are emerging as important medicines in cardiology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ommen, S. R. & Semsarian, C. Lancet 398, 2102–2108 (2021).
Marian, A. J. & Braunwald, E. Circ. Res. 121, 749–770 (2017).
Masri, A. & Olivotto, I. J. Am. Heart Assoc. 11, e024656 (2022).
Day, S. M., Tardiff, J. C. & Ostap, E. M. J. Clin. Invest. 132, e148557 (2022).
Green, E. M. et al. Science 351, 617–621 (2016).
Anderson, R. L. et al. Proc. Natl Acad. Sci. USA 115, E8143–E8152 (2018).
Rohde, J. A., Roopnarine, O., Thomas, D. D. & Muretta, J. M. Proc. Natl Acad. Sci. USA 115, E7486–E7494 (2018).
Lee, K. H. et al. Proc. Natl Acad. Sci. USA 115, E1991–E2000 (2018).
Olivotto, I. et al. Lancet 396, 759–769 (2020).
Spertus, J. A. et al. Lancet 397, 2467–2475 (2021).
Hegde, S. M. et al. J. Am. Coll. Cardiol. 78, 2518–2532 (2021).
Kumbhani, D. J. American College of Cardiology Meeting https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/01/02/42/VALOR-HCM (2022).
Ho, C. Y. et al. J. Am. Coll. Cardiol. 75, 2649–2660 (2020).
Chuang, C. et al. J. Med. Chem. 64, 14142–14152 (2021).
Teerlink, J. R. et al. N. Engl. J. Med. 384, 105–116 (2021).
Acknowledgements
A.C.C. was supported by NIH Medical Scientist Training Program Training Grant T32GM007739 and an American Heart Association Predoctoral Fellowship.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
S.M.D. receives research funding from Bristol Myers Squibb, consults for Tenaya Therapeutics and Pfizer, and is on the data monitoring board for Cytokinetics. A.C.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Chin, A.C., Day, S.M. Myosin modulators move forward with FDA approval of mavacamten. Nat Cardiovasc Res 1, 595–596 (2022). https://doi.org/10.1038/s44161-022-00093-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-022-00093-x